Fu Wei reports NovaBridge Biosciences (NBP) stakes via options and trusts
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
NovaBridge Biosciences director Fu Wei filed an initial statement of beneficial ownership, detailing option awards and indirect share holdings as of 2026-03-18. He holds 2025 Employee Share Options over Ordinary Shares with exercise prices of $3.1900 per ADS-equivalent and expirations on 2035-09-03, including tranches over 1,635,729 and 2,453,583 underlying Ordinary Shares. Footnotes explain that these options vest, if at all, in eight equal quarterly installments after the issuer’s ADSs maintain 30‑trading‑day weighted average prices at or above $8.00, $12.00, and $16.00 for different grants. Indirect Ordinary Share positions are reported through entities such as CBC Investment l‑Mab Limited, IBC Investment Seven Limited, CBC SPVII Limited, C‑Bridge II Investment Ten Limited and a family trust, with each block represented by specific ADS amounts including 5,123,549, 1,583,284, 2,423,721, 1,030,237 and 3,099,950 ADSs. The filing notes that each 10 ADSs represent 23 Ordinary Shares and that Fu Wei disclaims beneficial ownership of securities held by these entities and the trust except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Fu Wei
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | 2025 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2025 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2025 Employee Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
2025 Employee Share Option (right to buy) — 1,635,729 shares (Direct);
Ordinary Shares — 11,784,164 shares (Indirect, By CBC Investment l-Mab Limited)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Reported securities are represented by 5,123,549 ADSs. CBC Investment l-Mab Limited ("CBC:) is controlled by C-Bridge Healthcare Fund II, L.P. ("C-Bridge Healthcare"), C-Bridge Healthcare Fund GP II, L.P. ("C-Bridge Healthcare GP") is the general partner of C-Bridge Healthcare, C-Bridge Capital GP, Ltd. ("C-Bridge Capital") is the general partner of C-Bridge Healthcare GP and the Reporting Person may be deemed to control C-Bridge Capital. The Reporting Person disclaims beneficial ownership of the securities held directly by CBC except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Reported securities are represented by 1,583,284 ADSs. IBC Investment Seven Limited ("IBC") is controlled by l-Bridge Healthcare Fund, L.P. ("I-Bridge"), l-Bridge Healthcare GP, L.P. ("I-Bridge GP") is the general partner of I-Bridge, C-Bridge Capital is the general partner of I-Bridge GP and the Reporting Person may be deemed to control C-Bridge Capital. The Reporting Person disclaims beneficial ownership of the securities held directly by IBC except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Reported securities are represented by 2,423,721 ADSs. CBC SPVII Limited ("CBC SPVII") is controlled by I-Bridge, I-Bridge GP is the general partner of I-Bridge, C-Bridge Capital is the general partner of I-Bridge GP and the Reporting Person may be deemed to control C-Bridge Capital. The Reporting Person disclaims beneficial ownership of the securities held directly by CBC SPVII except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Reported securities are represented by 1,030,237 ADSs. C-Bridge II Investment Ten Limited ("C-Bridge") is controlled by C-Bridge Healthcare, C-Bridge Healthcare GP is the general partner of C-Bridge Healthcare, C-Bridge Capital is the general partner of C-Bridge Healthcare GP and the Reporting Person may be deemed to control C-Bridge Capital. The Reporting Person disclaims beneficial ownership of the securities held directly by C-Bridge except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Reported securities are represented by 3,099,950 ADSs. The securities are held through a trust which was established by the Reporting Person (as the settlor) for the benefit of the Reporting Person and his family. The Reporting Person disclaims beneficial ownership of these except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose Number of underlying securities and exercise price expressed in terms of ADSs. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$12.00. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$16.00.
FAQ
What does Fu Wei’s Form 3 for NovaBridge Biosciences (NBP) show?
The Form 3 shows Fu Wei’s initial reported holdings in NovaBridge Biosciences, including employee share options and indirect Ordinary Share stakes via several investment entities and a family trust, with detailed ADS equivalents and vesting conditions tied to future ADS price performance.
How are Fu Wei’s NovaBridge Biosciences (NBP) options structured?
Fu Wei holds 2025 Employee Share Options on Ordinary Shares at an exercise price of $3.1900 per ADS-equivalent, expiring on September 3, 2035. Different tranches vest, if at all, in eight quarterly installments after the ADS price sustains $8, $12, or $16 levels.
What indirect NovaBridge Biosciences (NBP) holdings are reported for Fu Wei?
Indirect Ordinary Share holdings are reported through CBC Investment l‑Mab Limited, IBC Investment Seven Limited, CBC SPVII Limited, C‑Bridge II Investment Ten Limited, and a family trust, with blocks represented by ADS amounts such as 5,123,549, 1,583,284, 2,423,721, 1,030,237 and 3,099,950 ADSs.